299 related articles for article (PubMed ID: 36327160)
41. An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously.
Wang Q; Wei R; Guo S; Min C; Zhong X; Huang H; Cheng Z
Cancer Gene Ther; 2024 Mar; 31(3):420-426. PubMed ID: 38102463
[TBL] [Abstract][Full Text] [Related]
42. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
43. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
D'Agostino M; Raje N
Leukemia; 2020 Jan; 34(1):21-34. PubMed ID: 31780814
[TBL] [Abstract][Full Text] [Related]
44. Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
Elnaggar M; Agte S; Restrepo P; Ram M; Melnekoff D; Adamopoulos C; Stevens MM; Kappes K; Leshchenko V; Verina D; Jagannath S; Poulikakos PI; Parekh S; Laganà A
J Hematol Oncol; 2022 Aug; 15(1):109. PubMed ID: 35978321
[TBL] [Abstract][Full Text] [Related]
45. Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy.
Shen Y; Liu J; Wang B; Zhang Y; Xu Y; Wang X; Jia Y; Meng X; Wang X; Fan X; He A; Zhao W
Curr Res Transl Med; 2023; 71(2):103378. PubMed ID: 36720180
[TBL] [Abstract][Full Text] [Related]
46. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
47. BCMA CAR-T cells in multiple myeloma-ready for take-off?
Scheller L; Tebuka E; Rambau PF; Einsele H; Hudecek M; Prommersberger SR; Danhof S
Leuk Lymphoma; 2024 Feb; 65(2):143-157. PubMed ID: 37997705
[TBL] [Abstract][Full Text] [Related]
48. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
[TBL] [Abstract][Full Text] [Related]
49. [Future therapeutic strategies for multiple myeloma].
Ishida T
Rinsho Ketsueki; 2022; 63(6):635-645. PubMed ID: 35831199
[TBL] [Abstract][Full Text] [Related]
50. [The characteristics and impact on prognosis of cytopenia after anti-BCMA-CAR-T therapy in patients with relapsed and refractory multiple myeloma].
Shen XX; Yao Y; Xia Y; Jin YY; Zhang R; Li JY; Chen LJ
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):507-513. PubMed ID: 38317362
[No Abstract] [Full Text] [Related]
51. BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.
Lu Q; Li H; Wu Z; Zhu Z; Zhang Z; Yang D; Tong A
J Nanobiotechnology; 2024 May; 22(1):279. PubMed ID: 38783333
[TBL] [Abstract][Full Text] [Related]
52. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.
Xu J; Wang BY; Yu SH; Chen SJ; Yang SS; Liu R; Chen LJ; Hou J; Chen Z; Zhao WH; He AL; Mi JQ; Chen SJ
J Hematol Oncol; 2024 Apr; 17(1):23. PubMed ID: 38659046
[TBL] [Abstract][Full Text] [Related]
53. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.
Hashmi H; Hansen DK; Peres LC; Puglianini OC; Freeman C; De Avila G; Sidana S; Shune L; Sborov DW; Davis J; Wagner C; Kocoglu MH; Atrash S; Voorhees P; Simmons G; Ferreri C; Kalariya N; Anderson LD; Afrough A; Dima D; Khouri J; McGuirk J; Locke F; Baz R; Patel KK; Alsina M
Haematologica; 2024 May; 109(5):1514-1524. PubMed ID: 37855036
[TBL] [Abstract][Full Text] [Related]
54. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.
Roex G; Timmers M; Wouters K; Campillo-Davo D; Flumens D; Schroyens W; Chu Y; Berneman ZN; Lion E; Luo F; Anguille S
J Hematol Oncol; 2020 Dec; 13(1):164. PubMed ID: 33272302
[TBL] [Abstract][Full Text] [Related]
55. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
Yang J; Zhou W; Li D; Niu T; Wang W
Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
[TBL] [Abstract][Full Text] [Related]
56. Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.
Reyes KR; Huang CY; Lo M; Arora S; Chung A; Wong SW; Wolf J; Olin RL; Martin T; Shah N; Banerjee R
Transplant Cell Ther; 2023 Jun; 29(6):350-355. PubMed ID: 36933659
[TBL] [Abstract][Full Text] [Related]
57. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
[TBL] [Abstract][Full Text] [Related]
58. GPRC5D-Targeted CAR T Cells for Myeloma.
Mailankody S; Devlin SM; Landa J; Nath K; Diamonte C; Carstens EJ; Russo D; Auclair R; Fitzgerald L; Cadzin B; Wang X; Sikder D; Senechal B; Bermudez VP; Purdon TJ; Hosszu K; McAvoy DP; Farzana T; Mead E; Wilcox JA; Santomasso BD; Shah GL; Shah UA; Korde N; Lesokhin A; Tan CR; Hultcrantz M; Hassoun H; Roshal M; Sen F; Dogan A; Landgren O; Giralt SA; Park JH; Usmani SZ; Rivière I; Brentjens RJ; Smith EL
N Engl J Med; 2022 Sep; 387(13):1196-1206. PubMed ID: 36170501
[TBL] [Abstract][Full Text] [Related]
59. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
Ferreri CJ; Hildebrandt MAT; Hashmi H; Shune LO; McGuirk JP; Sborov DW; Wagner CB; Kocoglu MH; Rapoport A; Atrash S; Voorhees PM; Khouri J; Dima D; Afrough A; Kaur G; Anderson LD; Simmons G; Davis JA; Kalariya N; Peres LC; Lin Y; Janakiram M; Nadeem O; Alsina M; Locke FL; Sidana S; Hansen DK; Patel KK; Castaneda Puglianini OA
Blood Cancer J; 2023 Aug; 13(1):117. PubMed ID: 37558706
[TBL] [Abstract][Full Text] [Related]
60. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
